CUE VS MRK Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatilityDividend

Performance

CUE
10/100

CUE returned -33.33% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

MRK
100/100

MRK returned 1.78% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

CUE
75/100

1 analysts offer 12-month price targets for CUE. Together, they have an average target of 7, the most optimistic target put CUE at 7 within 12-months and the most pessimistic has CUE at 7.

MRK
68/100

21 analysts offer 12-month price targets for MRK. Together, they have an average target of 113.88, the most optimistic target put MRK at 294 within 12-months and the most pessimistic has MRK at 80.

Sentiment

CUE
74/100

CUE had a bullish sentiment score of 74.32% across Twitter and StockTwits over the last 12 months. It had an average of 2.59 posts, 1.65 comments, and 3.88 likes per day.

MRK

"Sentiment" not found for MRK

Technicals

CUE
64/100

CUE receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

MRK
10/100

MRK receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

CUE
10/100

CUE has missed earnings 6 times in the last 20 quarters.

MRK
53/100

MRK has missed earnings 3 times in the last 20 quarters.

Profit

CUE
10/100

Out of the last 20 quarters, CUE has had 0 profitable quarters and has increased their profits year over year on 0 of them.

MRK
66/100

Out of the last 20 quarters, MRK has had 17 profitable quarters and has increased their profits year over year on 7 of them.

Volatility

CUE
40/100

CUE has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.

MRK
52/100

MRK has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.

Dividend

CUE

"Dividend" not found for CUE

MRK
100/100

MRK's most recent dividend was $0.47 per share, based on a share price of $101.35. It was a payout ratio of 69.90% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Cue Biopharma, Inc. Summary

Nasdaq / CUE
Healthcare
Biotechnology
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Merck & Co., Inc. Summary

New York Stock Exchange / MRK
Healthcare
Drug Manufacturers - General
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.